-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Autolus Therapeutics, Lowers Price Target to $6

Benzinga·03/21/2025 19:00:29
Listen to the news
Wells Fargo analyst Yanan Zhu maintains Autolus Therapeutics (NASDAQ:AUTL) with a Overweight and lowers the price target from $8 to $6.